Empagliflozin Increases Cardiac Energy Production in Diabetes

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Empagliflozin: Novel antidiabetes and pro-cardiac drug

Empagliflozin has been shown to improve glycaemic control and reduce CV mortality along with salutary effects on renal outcomes as compared to placebo in a recently conducted EMPA-REG OUTCOME trial in a large number of patients.[1,2] In this study, more than 7000 patients were randomly assigned to receive empagliflozin in the dose of 10 mg or 25 mg or placebo once daily. Patients were followed ...

متن کامل

Energy Production in Cardiac Isotonic Contractions

The energy output of rabbit papillary muscle is examined and it is shown that there is more energy liberated in an afterloaded isotonic contraction than in an "equivalent" isometric contraction. This statement holds true regardless of whether equivalence is based on the proposition that tension or the time integral of tension is the best index of muscle energy expenditure. Besides the external ...

متن کامل

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

BACKGROUND The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovas...

متن کامل

Diabetes and ischemia: similarities in cardiac energy metabolism

Ischemic heart disease (IHD) and diabetes mellitus (DM) are leading causes of death worldwide. Cardiac energy metabolism is profoundly altered in both of these conditions, which can lead to permanent cardiac pathologies that include heart failure and diabetic cardiomyopathy. Diabetic hearts show an increased dependence on oxidation of fatty acids for the production of adenosine triphosphate (AT...

متن کامل

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy

Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other antidiabetic agents that proved cardiovascular safety by non-inferiority compared with standard tr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: JACC: Basic to Translational Science

سال: 2018

ISSN: 2452-302X

DOI: 10.1016/j.jacbts.2018.07.006